Insulet (NASDAQ:PODD) Price Target Cut to $175.00 by Analysts at Citigroup

Insulet (NASDAQ:PODD) had its target price decreased by Citigroup from $230.00 to $175.00 in a research note released on Thursday morning,MarketScreener reports.

Several other analysts have also recently weighed in on PODD. Robert W. Baird lowered their price target on Insulet from $360.00 to $248.00 in a report on Thursday. BTIG Research lowered their price target on Insulet from $320.00 to $260.00 and set a “buy” rating on the stock in a report on Wednesday. Leerink Partners lowered their price target on Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Sanford C. Bernstein lowered their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Evercore lowered their price target on Insulet from $340.00 to $240.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Eighteen analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $257.09.

Insulet Stock Performance

NASDAQ:PODD opened at $160.40 on Thursday. The business’s 50-day moving average price is $211.22 and its two-hundred day moving average price is $263.85. Insulet has a twelve month low of $148.30 and a twelve month high of $354.88. The stock has a market cap of $11.11 billion, a P/E ratio of 37.30, a PEG ratio of 0.89 and a beta of 1.20. The company has a quick ratio of 2.15, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter last year, the firm posted $1.02 EPS. The company’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts predict that Insulet will post 6.27 EPS for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Michael R. Minogue bought 2,030 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the purchase, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Institutional Trading of Insulet

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Earned Wealth Advisors LLC purchased a new stake in Insulet in the first quarter worth approximately $236,000. Dimensional Fund Advisors LP boosted its stake in Insulet by 4.0% in the first quarter. Dimensional Fund Advisors LP now owns 369,197 shares of the medical instruments supplier’s stock worth $77,470,000 after buying an additional 14,080 shares in the last quarter. SEB Asset Management AB purchased a new stake in Insulet in the first quarter worth approximately $24,700,000. Swiss National Bank grew its position in Insulet by 7.1% during the 1st quarter. Swiss National Bank now owns 206,500 shares of the medical instruments supplier’s stock worth $43,332,000 after acquiring an additional 13,600 shares during the last quarter. Finally, Angeles Wealth Management LLC grew its position in Insulet by 5.3% during the 1st quarter. Angeles Wealth Management LLC now owns 2,725 shares of the medical instruments supplier’s stock worth $572,000 after acquiring an additional 136 shares during the last quarter.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 beat and guidance raise — Insulet reported Q1 revenue of $761.7M (+33.9% YoY) and adjusted EPS $1.42, topping estimates; management raised FY2026 constant‑currency revenue growth to 21%–23% and reiterated margin expansion, which helped lift sentiment. Business Wire: Q1 Results
• Positive Sentiment: Omnipod international momentum — Management highlighted sharp international Omnipod revenue growth and continued geographic expansion (including new Middle East Omnipod 5 launches), supporting growth durability beyond the U.S. market. Reuters: Growth/Forecast
• Positive Sentiment: Profitability and insider buying — Adjusted operating margin expanded and EPS beat consensus; several insiders (including the CEO) bought shares recently, which can signal management confidence. QuiverQuant: Earnings analysis & insider activity
• Neutral Sentiment: Analyst ratings still mixed — Several firms reiterated buy/overweight stances even as they trimmed targets; median analyst targets remain well above current levels, leaving upside claims but greater dispersion in near‑term expectations. QuiverQuant: Analyst moves & targets
• Negative Sentiment: Widespread price‑target cuts — Multiple brokers lowered targets (Piper Sandler, BofA/JPMorgan/others), reflecting model resets after the print; that put near‑term pressure on sentiment despite the beat. MarketScreener: Piper Sandler target cut

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.